Zura Bio (ZURA) Projected to Post Earnings on Thursday

Zura Bio (NASDAQ:ZURA) is expected to issue its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.17) per share for the quarter.

Zura Bio Stock Performance

NASDAQ:ZURA opened at $1.35 on Tuesday. Zura Bio has a 52 week low of $1.07 and a 52 week high of $6.35. The company has a fifty day simple moving average of $1.50 and a two-hundred day simple moving average of $2.78.

Analysts Set New Price Targets

ZURA has been the subject of several analyst reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Zura Bio in a research note on Wednesday, December 11th. HC Wainwright reissued a “neutral” rating and set a $5.00 price objective on shares of Zura Bio in a research report on Tuesday, December 24th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $15.80.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Zura Bio stock. Bank of America Corp DE increased its holdings in shares of Zura Bio Limited (NASDAQ:ZURA) by 31.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 41,222 shares of the company’s stock after purchasing an additional 9,966 shares during the quarter. Bank of America Corp DE owned approximately 0.06% of Zura Bio worth $103,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 61.14% of the company’s stock.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.